Company intelligence / Profile preview
Model Medicines
La Jolla, California, United Statesmodelmedicines.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
MDL-001, their lead antiviral compound, has completed two Phase 1 clinical trials with ~100 healthy subjects, demonstrating safety and tolerability at doses up to 200 mg/day for 28 days. The compound shows broad-spectrum antiviral activity with favorable pharmacokinetics including lung accumulation 10-40 times higher than EC50 values[3].
- Therapeutic areas
- GastroenterologyMetabolic DisordersOncologyNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Validated by researchers at academic and corporate laboratories
Beyond the preview
Go deeper on Model Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Model Medicines.